Bipolar disorder
Conditions
Interventions
Observation group(Bipolar disorder depressive episode. Drug intervention: Sertraline, quetiapine and combined with magnesium valproate were given in the case group, and blood lipid metabolomics level
control group (Venous blood was collected for lipid metabolomics.):None
Sponsors
Ningxia Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 29 Years
Inclusion criteria
Inclusion criteria: Case group:?All patients met the criteria for DSM-V diagnosis of depressive episodes with bipolar II disorder without psychotic symptoms (two or more attending doctors clearly diagnosed depressive disorders according to the criteria);? Between the ages of 18 and 29; ? The total score of the 17-item HAMD depression scale was =17 points;? Female subjects were required to consent to effective contraceptive use prior to enrollment and throughout the study. Fertile female subjects must have a negative urine pregnancy test at the time of screening; ? The informed consent is signed by the patient and/or legal guardian. Control group :? no diagnosis of mental illness;?Age: 18-29 years old; ? No history of major physical diseases and genetic history; ? Sign informed consent.
Exclusion criteria
Exclusion criteria: Case group:? Physical diseases, endocrine diseases, heart diseases, immune system related diseases, etc.; ?Acute and chronic infection within a month; ? Used drugs that affect lipid metabolism within 2 weeks; ? Those who have participated in strenuous exercise within 1 week; Alcohol or drug abusers; ? Taking antipsychotic drugs within 1 month before enrollment;;? 6 months before the group received electrical convulsions or brain stimulation treatment; ? Severe abnormal liver and kidney function;? People who are receiving hypoglycemic drugs, antihypertensive drugs, lipid-lowering drugs and drugs that affect uric acid levels; ? Severe cardiovascular disease;? Lactating or pregnant women; Diseases of the blood system. Control group :? serious physical disease or recently undergone surgery; ? Patients with organic brain diseases or dementia; ? Pregnant or lactating women; ? Drug abusers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes of blood lipid metabolomics after 0, 3 and 8 weeks of medication;Hamilton depression scale;Hamilton Anxiety Scale;Young manic rating scale;Negative symptom scale;Negative symptom scale;Non-suicidal self-injury behavior;Drug efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Suicide risk; | — |
Countries
China
Contacts
Public ContactChenYanhua
Mental Health Center, General Hospital of Ningxia Medical University
Outcome results
None listed